Pfizer is developing a bivalent vaccine for children ages 5 to 11, while Moderna’s would be eligible for those ages 6 to 17.
“If authorized by FDA, CDC anticipates a recommendation for bivalent COVID-19 vaccine as a booster for pediatric age groups in early to mid-October,” the agency said. “It is expected that if bivalent boosters are authorized for individuals aged 5 years and older as a booster, monovalent mRNA COVID-19 vaccines may no longer be authorized as booster doses.”
At present, Pfizer’s updated booster is authorized for people 12 and up, and Moderna’s is authorized for adults 19 and older. The CDC formally recommended the boosters for these age groups Sept. 1, one day after the FDA granted emergency use authorization.
Learn more here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.